Intravenous compared to oral busulfan with cyclophosphamide for autologous hematopoietic cell transplant conditioning for plasma cell myeloma

Abstract

s / Biol Blood Marrow Transplant 19 (2013) S178eS193 S190 (calculated from diagnosis) was 131 months and the fiveyear overall survival rate was 55.5%. Conclusions: In our experience, ASCT was associated with excellent disease control and outcomes in patients with relapsed refractory LPHL.